Bullpen.News From Edwin Dorsey
Get Daily Recap Feedback

Friday, October 23, 2026

Back to today

Research & Analysis: ERock, Inc. (NYSE: EROC)

ERock’s modular microgrids bridge data-center power gaps years before grid interconnects, with Meta and Anthropic projects filling capacity through early 2028.

EROC $453M
Monte Independent Investment Research 6 clicks

From X

@StableBread 1 click

Fajasy on X

AI labs and data labeling companies (firms that turn experts’ knowledge into training data for the labs) could make my $12-19M sale range for Nubeva Technologies $NBVAF (TSXV: $NBVA) look conservative. My previous write-up’s sale comps were five cybersecurity companies buying small startups that detect, stop, or recover from ransomware, and I valued a Nubeva sale at $12-19M, the low end of those deals. AI labs and data labeling companies would widen the set of buyers beyond cybersecurity companies, but I found none that has bought a ransomware recovery company like Nubeva. The closest deals were for a stake in a ransomware recovery company, malware data, and specialist teams: → Microsoft $MSFT: Made an equity investment in Veeam, a data protection and ransomware recovery company, in February 2025, as part of a partnership to build AI-based threat detection and other Microsoft AI services into Veeam’s products. → Google $GOOGL: Owns VirusTotal, a malware-scanning site it bought in 2012, and Mandiant, the incident-response firm it bought for $5.4B in 2022. Its experimental Sec-Gemini model, introduced in April 2025, draws on Mandiant’s threat intelligence data. → OpenAI: Agreed to buy Promptfoo in March 2026 for an undisclosed price. Promptfoo, which tests AI systems for security holes, was valued at $86M after its July 2025 funding round, per PitchBook. → Mercor (a data labeling company): Agreed to buy Deeptune, which builds practice environments for AI agents, in July 2026, months after Andreessen Horowitz led Deeptune’s $43M Series A. The two 2026 deals didn’t disclose prices, and Mandiant and Veeam are far larger businesses than Nubeva, so I can’t put a new number on a sale. Still, my $12-19M range is probably conservative now, since it only counted cybersecurity companies as buyers, and an AI lab or data labeling company would be paying for Nubeva’s engineers and model rather than its ~$500K of FY2026 revenue. But an AI buyer wouldn’t get patents on what it’s paying for. Nubeva’s patents would cover how it recovers files and how it detects hidden encryption, but it won’t patent its binary analysis (figuring out what malware programs do) at all, and CEO Randy Chou explained why: “Anything you patent, that means you have to show how you did it. If you show how you did it, well, somebody can train an LLM to go do it.” So the model is only worth what Nubeva can prove it does, through a signed contract, a named partner, or test results.

Investor Letters

All letters

Mosaic, Part One: The Story

Mosaic’s history traces the 2004 Cargill-IMC merger and the phosphate and potash mines that shaped NYSE: MOS.

MOS $5.5B
Latticework by MOI Global 26 clicks

Mosaic, Part Two: The Deep Dive

Mosaic, NYSE: MOS, is the subject of a second audio program for professional investors analyzing fertilizer producers.

MOS $5.5B
Latticework by MOI Global 4 clicks

Unicycive (UNCY):

Unicycive’s oxylanthanum carbonate NDA earned a March 25, 2027 PDUFA date after two manufacturing-related rejections, with no FDA clinical…

UNCY $108M
Triple S Special Situations Investing 4 clicks

Moon River Moly: Research Note

Moon River Moly’s updated Davidson PEA lifts after-tax NPV to $1.24 billion as flotation raises tungsten output 350% and cuts molybdenum…

MRIVF $16M
Atrium Research - Equity Research 4 clicks

GLOO, part two

Gloo faces related-party deals, insider-heavy IPO ownership, acquisition losses and $84.5 million of CEO-backed puts as it burns cash and…

GLOO $291M
Guardian Research 4 clicks
PYPD · long

Polypid LTD

PolyPid, an $80 million Israeli biotech, fell nearly 30% despite solving a clinical problem.

PYPD $103M
Value Investors Club

Why I sold OB pick for 26 SVM

Silvercorp’s falling Ying grades, prolonged GC suspension, El Domo execution risk and Chaarat funding needs weaken its valuation despite…

SVM $2B
The Oak Bloke 27 clicks

Vicor Update, Part Three

Vicor’s $66.6 million in AI power-delivery royalties generated about $50 million of operating profit, eclipsing its module business as…

VICR $8.1B
CV's Substack 28 clicks

Carecloud News

CareCloud may attract a private-equity buyer after its Q3 call, with acquiring enough shares the main obstacle to a take-private deal.

CCLD $74M
Calvin Blissett 10 clicks

Publications we follow

Every publication on this site, hand-picked.

129 publications

Newsletters 109

YouTube 4

Blogs 15

Seeking Alpha 56 of 248

Nominate a publication

X accounts we follow

Every account on this site, hand-picked.

90 accounts
Nominate an account

Investor letters we follow

190 firms

Sectors

Ordered by how often our editor reaches for them.